retatrutide glp-1 gip glucagon is a novel triple agonist peptide at the receptor, receptor, and receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to #tirzepatide. @LillyPad #medtwitter #endotwitter Retatrutide: A Promising Breakthrough for

These injectables are approved for adults with a BMI of 27 or higher who have weight-related medical conditions, like hypertension or type 2 diabetes

Cefaclor causes vagus nerve-mediated depression-like symptoms with gut dysbiosis in mice

For a 180-pound (82 kg) active adult, this translates to approximately 115130 grams of protein per day

MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID

Bo qun Bo qun sn phm ni kh thong, trnh nh nng trc tip

This is a sign that the gut microbiome is shifting